Anti-Mullerian Hormone Levels Before & After an Open Myomectomy

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Anti-Mullerian hormone (AMH) is a marker for ovarian reserve. It is well known that ovarian surgery for endometriosis lowers Anti-Mullerian hormone, but little is known for other surgeries. We seek to investigate the hormone variations before and after an open myomectomy.

Hypothesis: Anti-Mullerian hormone levels drop following surgery but return to normal levels in a few months

NCT number	NCT01723085
Study type	Observational
Source	OVO R & D
Contact
Status	Terminated
Phase
Start date	March 2012
Completion date	December 2015

	Status	Clinical Trial	Phase
	Completed	`NCT03131388` - Clinical Performance Evaluation of AMH Assay
	Active, not recruiting	`NCT00928044` - The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH)	N/A

Anti-Mullerian Hormone Levels Before and After an Open Myomectomy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms